HARLEYSVILLE, Pa., Sept. 15, 2022 /PRNewswire/ -- Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Novome Biotechnologies, a clinical-stage company that develops engineered oral microbial therapies. The company's novel delivery platform controls the colonization of therapeutically engineered bacteria, enabling first-in-class treatment of chronic disorders such as inflammatory bowel disease and enteric hyperoxaluria.
Microbiome outfit Novome Biotechnologies said Tuesday that it has now secured $43.5 million in new financing via a Series B round. The funds, according to the company, will be used to advance its lead candidate through an ongoing Phase IIa — and advance other candidates for a potential indication in inflammatory bowel disease.
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced the close of a $43.5 million Series B financing. The financing was led by Tencent, and includes new investors University of Minnesota, Navian Investments, Colorcon Ventures and Touchdown Ventures. Existing investors DCVC Bio, 5AM Ventures, Alta Partners and Alexandria Venture Investments also participated in the financing.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Novome nBiotechnologies, Inc., a clinical-stage biotechnology company developingnengineered cellular therapies for the gut, today announced positive nresults from a Phase 1 study of orally-administered NOV-001 in healthy nvolunteers. The Phase 1 study demonstrated the ability to safely ncolonize the human gut with a therapeutically engineered microbe and ncontrol its abundance via once-daily dosing of a prebiotic control nmolecule. Based on these results, Novome intends to commence a Phase 2a nstudy to evaluate preliminary efficacy in patients with enteric nhyperoxaluria.
Back at the beginning of 2020, Genentech vet Blake Wise jumped to a startup in the Bay Area called Novome, joining at the same time a syndicate came together to offer a $33 million launch round for a platform biotech out to colonize the gut with engineered strains of bacteria that work as therapeutics.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today announced a multi-year research collaboration and licensing agreement with Genentech, a member of the Roche Group to use Novome’s proprietary Genetically Engineered Microbial Medicines (GEMMs) platform to discover, engineer and develop bacterial strains that express and deliver specific therapeutically relevant molecules to targets in the human intestinal tract to treat diseases such as Inflammatory Bowel Disease (IBD).
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced the start of a Phase 1 clinical trial of NOV-001, a once-daily, orally-administered Genetically Engineered Microbial Medicine (GEMM) for the potential treatment of enteric hyperoxaluria. Patients with enteric hyperoxaluria are at increased risk of developing kidney stones and, in more severe cases, chronic kidney disease and kidney failure. There are no FDA-approved treatment options for these patients.
McLean to lead the Company’s enteric hyperoxaluria program into Phase 1/2a clinical proof-of-concept, and to advance its Genetically Engineered Microbial Medicines (GEMMs) platform to address additional high unmet need diseases